发明申请
US20050075355A1 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
有权
水诺酮取代的苯并咪唑酮和喹唑啉酮衍生物作为人类ORL1受体的激动剂
- 专利标题： Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
- 专利标题（中）： 水诺酮取代的苯并咪唑酮和喹唑啉酮衍生物作为人类ORL1受体的激动剂
-
申请号： US10952180申请日： 2004-09-29
-
公开(公告)号： US20050075355A1公开(公告)日： 2005-04-07
- 发明人: Jacobus Den Hartog , Samuel David , Daniel Jasserand , Gustaaf Van Scharrenburg , Herman Van Stuivenberg , Tinka Tuinstra
- 申请人： Jacobus Den Hartog , Samuel David , Daniel Jasserand , Gustaaf Van Scharrenburg , Herman Van Stuivenberg , Tinka Tuinstra
- 专利权人： SOLVAY PHARMACEUTICALS B.V.
- 当前专利权人： SOLVAY PHARMACEUTICALS B.V.
- 优先权： EP03103671.8 20031003
- 主分类号： A61K31/397
- IPC分类号： A61K31/397 ; A61K31/4025 ; A61K31/4184 ; A61K31/4523 ; A61K31/517 ; A61P29/02 ; C07D401/04 ; C07D403/04 ; A61K31/454 ; C07D43/04
摘要：
The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description
公开/授权文献
信息查询
